to you, time take for everyone joining thank the listen to to and in. Thank this you the We Paula, appreciate you afternoon. call
During from towards the contract manufacturing first quarter, for plans organization, an gene market. or medical the development company a to integrated and therapy CDMO, progress to our executing and device cell we are making transform
efficiently. future business. leverage and the and a March will goal support In private cell cheaper our processing technologies, planned cell more The semi-automated platform our to CDMO manufacture placement, gene launch CAR-TXpress closed million is unique to help and of automated which XXXX, $X we proprietary and the including therapies
highest of made significant therapy medicines, are Sacramento. institutions our ideal cleanrooms quicker we accelerate for scientific candidates and such safer. into developing will building These as have that next early-stage at in the requirements the cell XX,XXX be ReadyStart to companies that regulatory and To facility drug connect suites meet to quality CAR-T designed and cancer a foot end, generation headway out XX-unit square cGMP class-X and
customers manage solutions streamline risk. in is order predictability and the goal overall increased chain, for manufacturing to to establish Our supply
efforts to solution same and market who in this to therapy begun companies, looking have early-stage scale turnkey are gene development cell the life We to and their up science start facility. jump
ReadyStart these in suites quarter year. the the third expect cGMP of be We to - this available second customers to or for
years, of you series the over pioneered of the XX innovative know, a for and and products for manufacturing has automated development ThermoGenesis cell industry. cell and As technologies may specifically therapy banking
world's of In processing automated provider private and has technologies the smart public banks. and storage leading choice cryo the fact, cell ThermoGenesis most been cell automated for some for important of
storage all clinical samples smart million BioArchive system over to grade approved Our bio well process U.S. or XXX institutes and well CBUs, from of systems used cord warehoused has blood has a FDA, BLA units over AXP XX% close to been globally. our
manufacturing amassed years our properties invaluable. in the know-how the to addition we over cell gene In therapies, intellectual have that and are
part CDMO, therapies our FDA. personalized Driving for therapies. continued the potentials cell is been the the industry CAR-T growth Since to a cell gene X ship autologous of on XXXX, by the large approved have focusing and
to other trials for of CAR-T may or the several it care line the recently, in cell shown options. did second-line those been respond that can therapeutic therapies for who last therapies standard defense cell options, CAR-T patients, that as expand not therapy future. More have the approved such have there applications indicating outperform of were that CAR-T
to to therapies being grow. FDA CAR-T additional XXXX. potentially therapies, With cell cell FDA approvals therapy show XX as therapies approved for as starting reports as Recent that anticipate XX more such for received life-saving in commercialization annually, new the these with demand manufacturing approval, cell many the of industry continues
range therapy in working assets a globally solid of than than more in development X,XXX XXX arena companies tumors. we cell pipeline alone clinical and As U.S. are speak, blood targeting there and the more
research processing innovative small third-party cGMP Each anticipated efficiently. companies these to our manufacturers of companies to to medical suites enabling medium-sized well-income for centers, were grow. majority and of more the faster their ReadyStart continue milestone flexible achieve a and biotech driven medium-sized to demand will research by While a small option, provide
affairs quality our to Additionally, strong product on will products, and running while customers' GMP of science, with manage their the team's the associated will development commercialization accelerate allowing expertise regulatory in regulatory our them facility. a help focus ThermoGenesis and compliance
have address strong and gene cutting-edge increased expertise, technology demand and the new for manufacturer the ThermoGenesis' facility intellectual positioning, therapy capabilities. to property service will With our manufacturing cell ability
cell cGMP We few will therapy the field customers remain units in focused on in CDMO the service ReadyStart gene to and next and launching the months.
me And to Jeff? results call to quarter. for with the the the turn financial first over share Jeff let that, key
